A Swedish BioScience Company Will Run A Phase I/IIa Study Of Its Monoclonal Antibody, In Conjunction With Merck's Pembrolizumab...

Clearly miniscule in size, as to the behemoth that is Rahway, overall -- and it is being conducted through Merck's EU business development subsidiary -- but this is a nice piece of bio-business validation, for smallish BioInvent.

The company is located near the southern seaward tip of Sweden, in Lund -- and could see its financial future mightily enhanced if the combo trials go well, and it meets the ultimate primary endpoints, of overall survival -- in various solid tumor cancers.

Here's the bit, from The PharmaLetter:

. . .Swedish immuno-oncology specialist BioInvent International (Nasdaq Stockholm: BINV) announced a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co (NYSE: MRK) for a Phase I/IIa study of its monoclonal antibody BI-1910 in combination with the US pharma giant’s blockbuster cancer drug Keytruda (pembrolizumab). . . .

Now you know. Onward. . . and grinning, in spite of the wheeling snowflakes, this morning.

नमस्ते